WO2004096265A1 - Nutrient liquid containing human growth hormone and the preparation method thereof - Google Patents

Nutrient liquid containing human growth hormone and the preparation method thereof Download PDF

Info

Publication number
WO2004096265A1
WO2004096265A1 PCT/CN2003/000698 CN0300698W WO2004096265A1 WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1 CN 0300698 W CN0300698 W CN 0300698W WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
heme iron
weishengli
active peptide
minutes
Prior art date
Application number
PCT/CN2003/000698
Other languages
French (fr)
Chinese (zh)
Inventor
Shenggang Fan
Longjiang Huo
Ping Ju
Ningbo Feng
Original Assignee
Yantai Apollo Biotechnology, Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Apollo Biotechnology, Co., Ltd. filed Critical Yantai Apollo Biotechnology, Co., Ltd.
Priority to AU2003261569A priority Critical patent/AU2003261569A1/en
Publication of WO2004096265A1 publication Critical patent/WO2004096265A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/315Zinc compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH] (Somatotropin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention disclosed a nutrient liquid that could regulate immunity, delay senility. It composed of human growth hormone, amino acid, heme iron, sodium selenite, magnesium lactate and zinc gluconate. Each component of the nutrient liquid is treating with ozone and comminuting mechanically into nanometer powder.

Description

维生力口 液及其制备方法 技术领域  Vitality oral fluid and preparation method thereof
本发明涉及生物技术领域, 具体地讲是一种能延緩甚至逆转衰老, 增 强免疫功能的口服液及其制备方法。  The invention relates to the field of biotechnology, in particular to an oral solution capable of delaying or even reversing senescence and enhancing immune function, and a preparation method thereof.
背景技术 Background technique
随着人们生活节奏的加快, 精神压力与日倶增, 同时不规律的生活方 式已成为中国高收入人群的致病因素, 使他们身体老化速度加快。 特别是 脑力劳动者, 身体处于一种被医学界称之为 "亚健康" 的状态, 导致功能 年龄和生物年龄明显超过自然年龄, 给人一种未老先衰的感觉, 且这种趋 势越来越低龄化。 而现代社会在飞速发展, 人们的需求也在增加, 对生活 质量人们越来越重视, 目前市场上此类产品才刚刚起步, 各种相关产品在 质量和功效上叁差不齐。 虽然也有或多或少的效果, 但就当今目前来看, 对延缓特别是逆转衰老, 增强免疫功能的各种产品遇到了比较大的困难, 具体体现在: 1、 用量大, 副作用大。 比如, 一些注射用的产品, 效果比较 明显。 但它的用量太大, 宿主蛋白在人体内产生抗原反应, 甚至引起糖类、 脂肪、 蛋白质的代谢紊乱; 2、 现有的产品其活性因子的生理活性难以在常 温下持久保存, 没有相当活力, 效果就会大打折扣; 3、 活性成分的生物利 用度很低, 一般来讲, 活性成分通过血液进入细胞之后才会起作用, 市场 上的此类产品几乎是口服饮用, 导致这种活性成分在胃肠道被大部分分解 而失去活力; 4、 成本太高, 是一般消费者难以承受的。  With the acceleration of people's pace of life, mental stress and day-by-day increase, and irregular lifestyles have become a causative factor for high-income people in China, making them more aging. Especially for mental workers, the body is in a state called "sub-health" by the medical community, which causes the functional age and biological age to be significantly higher than the natural age. Coming younger and younger. While modern society is developing rapidly, people ’s demand is also increasing, and people are paying more and more attention to the quality of life. At present, such products on the market have just started, and various related products are uneven in quality and efficacy. Although it has more or less effects, at present, it has encountered relatively great difficulties in delaying aging, in particular reversing aging, and enhancing immune function of various products, which are specifically reflected in: 1. Large dosage and large side effects. For example, some injection products are more effective. However, its amount is too large, the host protein produces an antigen response in the human body, and even causes metabolic disorders of sugars, fats, and proteins; 2. The physiological activities of the active factors of the existing products are difficult to maintain at room temperature for a long time, and they are not quite active , The effect will be greatly reduced; 3. The bioavailability of the active ingredient is very low. Generally speaking, the active ingredient does not work until it enters the cell through the blood. Such products on the market are almost drinkable orally, which leads to this active ingredient It is mostly decomposed and loses vitality in the gastrointestinal tract; 4. The cost is too high, which is unbearable for ordinary consumers.
因而一种用量少、 副作用小、 成本低、 活性因子保存时间长、 活性成 分利用率高的一种维生力口服液未曾见到。  Therefore, a kind of Weishengli oral liquid with less dosage, small side effects, low cost, long storage time of active factors, and high utilization rate of active ingredients has never been seen.
发明内容 Summary of the Invention
. 本发明的目的旨在克服上述已有技术的不足,而提供一种能延缓衰老、 增强免疫功能的维生力口服液。 主要解决了现有产品用量大、 副作用大、 成本高、 活性因子保存时间短、 活性成分利用率低的问题。  The purpose of the present invention is to overcome the shortcomings of the prior art mentioned above and provide a vitality oral solution capable of delaying aging and enhancing immune function. It mainly solves the problems of large amount of existing products, large side effects, high cost, short storage time of active factors, and low utilization of active ingredients.
本发明的另一目的是提供维生力口威液的制备方法。 为了达到上述目的, 本发明是这样实现的: 维生力口服液, 它是由下 列组分按重量份组成,活性肽 0. 15-0. 50、氨基酸 50- 100、血红素铁 20-80、 亚硒酸钠 0. 30-0. 80、 乳酸镁 0. 18-0. 30、 葡萄糖酸锌 0. 25-0. 50。 Another object of the present invention is to provide a method for preparing a vitality liquid. In order to achieve the above object, the present invention is achieved as follows: Weishengli oral liquid, which is composed of the following components by weight parts, active peptides 0. 15-0. 50, amino acids 50- 100, heme iron 20-80 , Sodium selenite 0.30-0. 80, magnesium lactate 0.18-0. 30, zinc gluconate 0.25-0. 50.
为了进一步实现上述目的, 本发明的一种较好的实施方式为各组分重 量比是, 活性肽 0. 18-0. 40、 氨基酸 55-80、 血红素铁 30-60、 亚硒酸钠 0. 35 - 0. 60、 乳酸镁 0. 19-0. 25、 葡萄糖酸锌 0. 28-0. 40。  In order to further achieve the above objective, a preferred embodiment of the present invention is that the weight ratio of each component is: active peptide 0.18-0. 40, amino acid 55-80, heme iron 30-60, sodium selenite 0. 35-0. 60, magnesium lactate 0. 19-0. 25, zinc gluconate 0. 28-0. 40.
为了进一步实现上述的目的, 本发明的一种最好的实施方式为各组分 重量配比是, 活性肽 0. 20、 氨基酸 58、 血红素铁 35、 亚硒酸钠 G. 40、 乳 酸镁 0. 20、 葡萄糖酸锌 0. 30。  In order to further achieve the above-mentioned object, a best embodiment of the present invention is that the weight ratio of each component is: active peptide 0.20, amino acid 58, heme iron 35, sodium selenite G. 40, magnesium lactate 0. 20, zinc gluconate 0.30.
本发明所述的维生力口服液的制备方法, 它包括如下工艺步骤: 第一步, 臭氧处理。 称量各组分, 用臭氧进行处理;  The method for preparing the Weishengli oral liquid according to the present invention comprises the following process steps: The first step is ozone treatment. Weigh each component and treat it with ozone;
第二步, 制备纳米粉剂。 将氨基酸、 血红素铁放入复式高剪切破碎分 散机, 制备成纳米粉剂;  The second step is to prepare nano powder. Put amino acid and heme iron into compound high-shear crushing disperser to prepare nano powder;
第三步, 超声混合。 把纳米粉剂转入超声波混合器, 30分钟后加入活 性肽继续混合 60分钟, 冷冻至 -18 °C ;  The third step is ultrasonic mixing. Transfer the nano-powder into the ultrasonic mixer, add active peptides after 30 minutes, continue mixing for 60 minutes, and freeze to -18 ° C;
第四步, 混合。 在 2 °C条件下将各组分调配, 混合均匀;  The fourth step is mixing. Blend each component at 2 ° C, mix well;
第五步, 包装。 釆用无菌罐装, 制成成品。  The fifth step is packaging.釆 Use sterile cans to make finished products.
本发明所述的活性肽 HGH是 Human Growth Hormone 的缩写, 也称人 类生长素。 它是由内分泌腺体分泌的生理活性物质, 由 191个氨基酸分子 组成的人体最重要的荷尔蒙 (蛋白多肽), 是所有其它荷尔蒙的统帅。  The active peptide HGH of the present invention is an abbreviation of Human Growth Hormone, and is also called human growth hormone. It is a physiologically active substance secreted by the endocrine glands. The body's most important hormone (protein peptide), which is composed of 191 amino acid molecules, is the commander of all other hormones.
一般情况下, 当人的年龄达到 30岁后, 活性肽的分泌量慢慢减少。 由于, 它几乎参与人体的一切生命活动, 主控人体的生长发育、 免疫 调节和新陈代谢, 它分泌量的多少直接影响人体细胞、 骨骼、 软骨、 肌肉、 皮肤、 肝和肾等的生长发育。  In general, when a person reaches 30 years of age, the secretion of active peptides gradually decreases. Because it participates in almost all life activities of the human body, it controls the growth and development, immune regulation, and metabolism of the human body. The amount of its secretion directly affects the growth and development of human cells, bones, cartilage, muscles, skin, liver, and kidneys.
本发明的维生力口服液是基于传统医学对中药几千年的实践认识, 结 合现代药理研究成就和最新生物工程尖端技术, 按中医理论组方, 对人体 生殖、 生长、 新陈代谢、 免疫、 清除人体自由基, 一直到思维、 情绪具有 显著的功能。 它能抵抗疾病、 激活免疫系统, 使人减少生病、 增强体力、 使人精力充沛, 长时间工作而无疲倦感。 煥发人的精神面貌, 信心十足, 情绪高涨。 使皮肤、 骨骼恢复青春。 且是一种有效的减肥药, 重新塑造体 形, 有选择性的减少腰、 腹部深层脂肪和大腿脂肪, 同时增加肌肉。 使肝、 肺、 肾等脏器再生, 器官和组织的功能恢复到年轻水平。 The Weishengli oral liquid of the present invention is based on the traditional knowledge of traditional Chinese medicine for thousands of years, combined with the achievements of modern pharmacological research and the latest cutting-edge bioengineering technology. Human free radicals have significant functions all the way to thinking and emotion. It can fight diseases, activate the immune system, make people less sick, increase physical strength, Energizing, working long hours without feeling tired. Reveals a person's mental outlook, full of confidence, and high emotions. Revitalizes skin and bones. And it is an effective weight-loss medicine to reshape the body, selectively reduce deep fat in the waist, abdomen and thigh, and increase muscle. Regenerate organs such as liver, lungs, and kidneys, and restore organs and tissues to a younger level.
现代医学研究证明, 人之所以衰老, 是因为细胞内的 《端粒,' Modern medical research proves that the reason why people age is because of "telomeres,"
( Tel omero )随着细胞分裂而減少。 达到一定程度, "端粒', 消失, 细胞停 止分裂, 人就会衰老死亡。 (Tel omero) decreases with cell division. At a certain level, "telomeres" disappear, cells stop dividing, and people will age and die.
但是, 这种 "端粒" 受细胞核内 "端粒酶" (Te l omerase ) 的控制。 通常情况下, "端粒酶" 处于 "关闭" 状态, 活性肽 (如 HGH、 IFG-1 ) 活 性因子, 通过血液进入细胞, 它作用于 "端粒酶" 的 DNA, 激活端粒酶, 使其处于 "开放" 状态而增加端粒的长度, 从而延緩衰老。  However, this "telomere" is controlled by the "telomerase" in the nucleus. Normally, "telomerase" is in the "off" state, and active peptides (such as HGH, IFG-1) enter the cell through the blood, and it acts on the DNA of "telomerase", activates telomerase, and makes It is in an "open" state and increases the length of telomeres, thereby delaying aging.
事实上, 人的免疫系统在中老年人身上急剧衰退, 为各种传染病和癌 症打开了大门。 本发明的维生力口服液能促进人体内免疫因子的增加 (包 括: Cytokines , 白介素 1和 2 , 免疫球蛋白 G, 肿瘤坏死因子), 从而增强 免疫功能。  In fact, the human immune system has declined sharply in middle-aged and elderly people, opening the door to various infectious diseases and cancers. The Weishengli oral liquid of the present invention can promote the increase of immune factors in the human body (including: Cytokines, interleukins 1 and 2, immunoglobulin G, tumor necrosis factor), thereby enhancing the immune function.
本发明所述的维生力口服液, 提供人体重要的活性肽, 促进腺体的分 泌, 从而使人体细胞、 骨骼、 软骨、 肌肉、 皮肤、 肝和肾等健康发育, 延 緩衰老。 经检验其含有人体所需的多种氨基酸和微量元素, 各种指标远远 高于保健食品的标准, 其菌类的检测指标远远低于保健食品的标准要求。  The Weishengli oral liquid provided by the invention provides important active peptides of the human body and promotes the secretion of glands, thereby enabling healthy development of human cells, bones, cartilage, muscles, skin, liver and kidneys, and delaying aging. After inspection, it contains a variety of amino acids and trace elements required by the human body, and various indicators are far higher than the standards of health foods, and the detection indicators of their fungi are far lower than the standards of health foods.
本发明的维生力口服液服用后有明显的效果, 服用后第二天, 大部分 服用者出现深度睡眠; 第三天, 服用者体力增强, 疲劳感减弱, 面色变得 红润; 一周后, 皮肤湿润、 脱发减少、 精力增加、 伤口愈合快、 局部水肿 减轻、 疤痕变淡、 视力 (老花眼) 改善、 脂肪减少、 食欲增强、 性功能改 善、 女性干燥感减轻; 一月后, 记忆力明显增强、 白发减少, 色斑变淡, 面部细小皱紋消失, 黑眼圈变浅, 老年斑淡化、 腰部脂肪减少, 女性绝经 者可能恢复行经, 免疫力增强, 耐力增加, 精力充沛, 顽固性偏头痛、 高 血压、 眩暈者症状消失, 关节疼痛、 风湿、 腰肌劳损等陈旧疾病明显改善; 二个月, 肌肉强健度增加, 脂肪进一步减少, 体重调整趋于正常, 指、 趾 甲生长改善, 性功能增强, 力量增加, 皮肤滋润, 视力及夜视力增进, 脂 肪肝消失; 三个月, 经期症状减轻, 身体柔韧度增加, 伤口快速愈合, 肌 肉疼痛感快速消失, 肌肉尺寸增加, 各器官功能继续改善; 四个月, 与以 上效果相同, 一般说来各项疗效增加而渐趋一致; 五个月, 显著的体重减 轻和三围尺寸的缩小, 由于脂肪减少而肌肉组织强健度增加, 皮肤厚度、 弹性和韧性增加, 质地和外观改善, 头发密度增加而且具有健康有光泽; 六个月, 疗效与上述相同, 但效果更佳、 更稳定, 脂肪球体大量减少, 情 绪稳定, 视力大幅度增进, 旧伤痊愈或正在痊愈, 灰发转为原来的自然光 泽, 体形轮廓转佳、 精力旺盛、 运动耐力显著增强。 The Weishengli oral liquid of the present invention has obvious effects after taking it, and the majority of users take deep sleep on the second day after taking it; on the third day, the user's physical strength increases, fatigue is weakened, and his complexion becomes ruddy; one week later, Wet skin, reduced hair loss, increased energy, fast wound healing, reduced local edema, lightened scars, improved vision (presbyopia), reduced fat, increased appetite, improved sexual function, reduced female dryness; after one month, memory significantly increased, Decreased white hair, faded spots, disappeared small facial wrinkles, lightened dark circles, lightened age spots, decreased waist fat, female menopause may resume menstruation, increased immunity, increased endurance, energetic, refractory migraine, high blood pressure The symptoms of vertigo disappeared, and old diseases such as joint pain, rheumatism, and lumbar muscle strain improved significantly; two months, muscle strength increased, fat was further reduced, weight adjustment tended to be normal, fingers, toes Nail growth is improved, sexual function is enhanced, strength is increased, skin is moisturized, vision and night vision are improved, fatty liver disappears; three months, menstrual symptoms are reduced, body flexibility is increased, wounds heal quickly, muscle pain quickly disappears, muscle size increases The functions of various organs continued to improve; four months, the same effect as above, generally speaking, the effects increased and gradually became consistent; five months, significant weight loss and reduction in measurements, muscle strength due to reduced fat Increased skin thickness, elasticity and toughness, improved texture and appearance, increased hair density and healthy and shiny; six months, the effect is the same as above, but the effect is better and more stable, fat spheres are greatly reduced, emotional stability, vision It has been greatly improved. The old wound is healed or is being healed, the gray hair is turned to the original natural luster, the body shape is improved, the energy is vigorous, and the sports endurance is significantly enhanced.
2001年做的一次效果调查, 治疗的对象有 800人, 包括企业家, 高层 主管, 最多的是医生, 占 20°/。。 随机抽取 202名对象资料进行分析, 这 202 人的年龄从 36岁到 74岁, 妇女占 19% , 202人的平均治疗时间是 180天, 最短 1个月, 最长 2年。  An effect survey conducted in 2001 included 800 people, including entrepreneurs, senior executives, and most doctors, accounting for 20 °. . The data of 202 subjects were randomly selected for analysis. The 202 people ranged from 36 to 74 years old, and women accounted for 19%. The average treatment time of 202 people was 180 days, with a minimum of 1 month and a maximum of 2 years.
其结果如下: 解化病理的占 89% , 增加心脏收缩能力的占 84% , 降低 胆固醇的占 85% , 肌肉增加的占 81%, 脂肪减少的占 72%, 运动耐力提高的 占 81% ,皮肤厚度增加的占 68% ,皮肤弹性增加的占 71%,皱纹消失的占 61% , 伤口愈合能力提高的占 57% ,潮热减少的占 58% ,月经变得有规律的占 39%, 对生活增加信心的占 78% , 皮肤变细变白的占 70% , 精力增加的占 89% , 情 绪变稳定的占 73% , 抵抗一般疾病的占 70%, 记忆力增加的占 60% , 旧伤愈 合的占 55% , 头发新生的占 36%。  The results are as follows: 89% of pathological solutions, 84% of increased cardiac contractility, 85% of reduced cholesterol, 81% of increased muscle, 72% of reduced fat, and 81% of improved endurance, 68% increase in skin thickness, 71% increase in skin elasticity, 61% disappearance of wrinkles, 57% increase in wound healing ability, 58% decrease in hot flashes, and 39% regular menstruation. 78% increase confidence in life, 70% skin thinning and whitening, 89% increase in energy, 73% mood stabilization, 70% resistance to common diseases, 60% increase in memory, old 55% of wounds healed, and 36% were new hair.
调查结果: 治疗效果达 1 00%, 因而本发明的维生力口服液在延緩和逆 转衰老、 增强免疫功能方面有很好的效果。  Investigation results: The therapeutic effect reaches 100%, so the Weishengli oral liquid of the present invention has a very good effect in delaying and reversing aging and enhancing immune function.
本发明所述的维生力口服液与已有技术相比, 具有突出的实质性特点 和显著的进步:  Compared with the prior art, the Weishengli oral liquid according to the present invention has prominent substantive characteristics and significant progress:
1、 由于本发明采用纳米包埋技术,可以使活性因子的生理活性在常温下 保存达两年之久;  1. Because the present invention adopts nano-embedding technology, the physiological activity of the active factor can be kept at room temperature for two years;
2、 由于本发明采用口喷形式, 而不是口服, 可从舌下口腔黏膜直接吸收 进入血液微循环,从而避免活性成份在胃肠道被大部分分解而失去活 力; 2. As the present invention adopts the form of oral spray instead of oral administration, it can be directly absorbed from the oral mucosa under the tongue and enter the blood microcirculation, thereby avoiding the active ingredient being largely decomposed and inactivated in the gastrointestinal tract. Force
3、 使用方便、 用量少、 高效安全、 效果明显;  3. Easy to use, less dosage, efficient and safe, and obvious effect;
4、 成本低。  4. Low cost.
具体实施方式: detailed description:
为了更好地理解与实施, 下面结合实施例详细说明本发明维生力口服 液及其制备方法。  In order to better understand and implement, the Weishengli oral liquid of the present invention and the preparation method thereof will be described in detail below with reference to the examples.
实施例 1, 分别称量活性肽 0.20g、 氨基酸 58g、 血红素铁 35g、 亚硒 酸钠 0.40g、 乳酸镁 0.20g、 葡萄糖酸锌 0. 30g, 用臭氧进行处理。  Example 1. Weigh 0.20g of active peptide, 58g of amino acid, 35g of heme iron, 0.40g of sodium selenite, 0.20g of magnesium lactate, 0.30g of zinc gluconate, and treat with ozone.
将氨基酸、 血红素铁放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至- 18°C。 在 2°C下按各组分配比调配, 混匀, 而后进行无 菌罐装, 制成本发明的维生力口服液。  The amino acid and heme iron were put into a compound high-shear crushing and dispersing machine to prepare nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
实施例 2, 分别称量活性肽 0. 30g、 氨基酸 80g、 血红素铁 40g、 亚硒 酸钠 0.46g、 乳酸镁 0.18g、 葡萄糖酸辞 0. 35g, 用臭氧进行处理。  Example 2. Weigh 0.30 g of active peptide, 80 g of amino acid, 40 g of heme iron, 0.46 g of sodium selenite, 0.18 g of magnesium lactate, and 0.35 g of gluconate, respectively, and treat with ozone.
将氨基酸、 血红素鉄放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至- 18°C。 在 2°C下按各组分配比调配, 混匀, 而后进行无 菌罐装, 制成本发明的维生力口服液。  The amino acid and heme hydrazone were put into a compound high-shear crushing disperser to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
实施例 3, 分别称量活性肽 0. 18g、 氨基酸 55g、 血红素铁 30g、 亚硒 酸钠 0. 35g、 乳酸镁 0.19g、 葡萄糖酸鋅 0.28g, 用臭氧进行处理。  In Example 3, 0.18 g of active peptide, 55 g of amino acid, 30 g of heme iron, 0.35 g of sodium selenite, 0.19 g of magnesium lactate, and 0.28 g of zinc gluconate were weighed, respectively, and treated with ozone.
将氨基酸、 血红素铁放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至- 18°C。 在 2°C下按各组分配比调配, 混勾, 而后进行无 菌罐装, 制成本发明的维生力口服液。  The amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed with hooks, and then sterilized canned to prepare the vitality oral solution of the present invention.
实施例 4, 分别称量活性肽 0.40g、 氨基酸 80g、 血红素铁 60g、 亚硒 酸钠 0.60g、 乳酸镁 0.25g、 葡萄糖酸锌 0.40g, 用臭氧进行处理。  Example 4. Weigh 0.40 g of active peptide, 80 g of amino acid, 60 g of heme iron, 0.60 g of sodium selenite, 0.25 g of magnesium lactate, and 0.40 g of zinc gluconate, respectively, and treat with ozone.
将氨基酸、 血红素铁放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至 -18°C。 在 2°C下按各组分配比调配, 混匀, 而后进行无 菌罐装, 制成本发明的维生力口服液。 The amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nano powder to the ultrasonic mixer, add active peptide after 30 minutes and continue mixing for 60 minutes Minutes, then frozen to -18 ° C. Formulated according to the distribution ratio of each group at 2 ° C, mixed, and then aseptically canned to prepare the vitality oral solution of the present invention.
实施例 5, 分别称量活性肽 0.15g、 氨基酸 50g、 血红素铁 20g、 亚硒 酸钠 0.30g、 乳酸镁 0.18g、 葡萄糖酸锌 0.25g, 用臭氧进行处理。  Example 5, 0.15 g of active peptide, 50 g of amino acid, 20 g of heme iron, 0.30 g of sodium selenite, 0.18 g of magnesium lactate, and 0.25 g of zinc gluconate were weighed, respectively, and treated with ozone.
将氨基酸、 血红素铁放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至 -18°C。 在 2°C下按各组分配比调配, 混匀, 而后进行无 菌罐装, 制成本发明的维生力口服液。  The amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
实施例 6, 分别称量活性肽 0.50g、 氨基酸 100g、 血红素铁 80g、 亚 硒酸钠 0.80g、 乳酸镁 0.30g、 葡萄糖酸锌 0.50g, 用臭氧进行处理。  In Example 6, 0.50 g of active peptide, 100 g of amino acid, 80 g of heme iron, 0.80 g of sodium selenite, 0.30 g of magnesium lactate, and 0.50 g of zinc gluconate were weighed and treated with ozone.
将氨基酸、 血红素铁放入复式高剪切破碎分散机, 制备成纳米粉剂。 把纳米粉剂转入超声波混合器, 30分钟后加入活性肽并继续混合 60 分钟, 然后冷冻至- 18°C。 在 2°C下按各组分配比调配, 混匀, 而后进行无 菌罐装, 制成本发明的维生力口服液。  The amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.

Claims

权 利 要 求 书 Claim
1、 一种维生力口服液, 其特征在于: 它是由下列组分按重量份组成, 活性肽 0. 15-0. 50、氨基酸 50-100、血红素铁 20-80、亚硒酸钠 0. 30-0. 80、 乳酸镁 0. 18 - 0. 30、 葡萄糖酸锌 0. 25-0. 50。  1. A Weishengli oral liquid, characterized in that it is composed of the following components in parts by weight, active peptide 0. 15-0. 50, amino acid 50-100, heme iron 20-80, selenite Sodium 0. 30-0. 80, magnesium lactate 0. 18-0. 30, zinc gluconate 0. 25-0. 50.
2、按权利要求 1所述的维生力口服液, 其特征在于: 所述的各组分重 量配比是, 活性肽 0. 18-0. 40、 氨基酸 55-80、 血红素铁 30-60、 亚硒酸钠 0. 35-0. 60、 乳酸镁 0. 19-0. 25、 葡萄糖酸锌 0. 28-0. 40。  2. The Weishengli oral liquid according to claim 1, characterized in that: the weight ratio of each component is, active peptide 0.18-0. 40, amino acid 55-80, heme iron 30- 60. Sodium selenite 0.35-0. 60, magnesium lactate 0.19-0. 25, zinc gluconate 0. 28-0. 40.
3、按权利要求 2所述的维生力口服液, 其特征在于: 所述的各组分重 量配比是, 活性肽 0. 20、 氨基酸 58、 血红素铁 35、 亚硒酸钠 0. 40、 乳酸 镁 0. 20、 葡萄糖酸锌 0. 30。  3. The Weishengli oral liquid according to claim 2, characterized in that: the weight ratio of each component is: active peptide 0.20, amino acid 58, heme iron 35, sodium selenite 0. 40, magnesium lactate 0.20, zinc gluconate 0.30.
4、权利要求 1-3所述的任意一种维生力口服液的制备方法,其特征在 于: 包括如下工艺步驟:  4. The method for preparing any of the Weishengli oral liquids according to claims 1-3, characterized in that it comprises the following process steps:
第一步, 臭氧处理, 称量各组分, 用臭氧进行处理;  The first step is ozone treatment, each component is weighed and treated with ozone;
第二步, 制备纳米粉剂, 将氨基酸、 血红素铁放入复式高剪切破碎分 散机, 制备成纳米粉剂;  In the second step, a nano powder is prepared, and the amino acid and heme iron are placed in a compound high-shear crushing disperser to prepare a nano powder.
第三步, 超声混合, 把纳米粉剂转入超声波混合器, 30分钟后加入活 性肽并继续混合 60分钟, 冷冻至 - 18 °C ;  The third step is ultrasonic mixing. The nanopowder is transferred into an ultrasonic mixer. After 30 minutes, the active peptide is added and mixing is continued for 60 minutes, and frozen to -18 ° C;
第四步, 混合, 在 2 °C条件下将各组分调配, 混合均匀;  The fourth step is mixing, and the components are blended at 2 ° C to mix evenly;
第五步, 包装, 采用无菌罐装, 制成成品。  The fifth step is packaging, using aseptic canning, to make the finished product.
PCT/CN2003/000698 2003-04-30 2003-08-20 Nutrient liquid containing human growth hormone and the preparation method thereof WO2004096265A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003261569A AU2003261569A1 (en) 2003-04-30 2003-08-20 Nutrient liquid containing human growth hormone and the preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN03112375A CN1449819A (en) 2003-04-30 2003-04-30 Weishengli oral liquid medicine and preparation process thereof
CN03112375.9 2003-04-30

Publications (1)

Publication Number Publication Date
WO2004096265A1 true WO2004096265A1 (en) 2004-11-11

Family

ID=28684011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000698 WO2004096265A1 (en) 2003-04-30 2003-08-20 Nutrient liquid containing human growth hormone and the preparation method thereof

Country Status (3)

Country Link
CN (1) CN1449819A (en)
AU (1) AU2003261569A1 (en)
WO (1) WO2004096265A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932524A1 (en) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmaceutical preparations for treating inflammatory diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104434A (en) * 1993-11-13 1995-07-05 西安宝安生物工程有限公司 Lactic full nutrient and its production
CN1368383A (en) * 2001-02-09 2002-09-11 济南百伦思营养食品有限公司 Precision and preparing process of health-care compound hormone product

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104434A (en) * 1993-11-13 1995-07-05 西安宝安生物工程有限公司 Lactic full nutrient and its production
CN1368383A (en) * 2001-02-09 2002-09-11 济南百伦思营养食品有限公司 Precision and preparing process of health-care compound hormone product

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932524A1 (en) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmaceutical preparations for treating inflammatory diseases

Also Published As

Publication number Publication date
AU2003261569A1 (en) 2004-11-23
CN1449819A (en) 2003-10-22

Similar Documents

Publication Publication Date Title
CA2634953C (en) Formulations and treatments for well-being
CN109172491A (en) A kind of creme and preparation method thereof with anti-aging and activating microcirculation and removing stasis medicinal function
CN111388650A (en) Composition for balancing male hormone and enhancing male charm and preparation method thereof
JPH05505819A (en) Compositions and methods for treating acne vulgaris and delaying aging
Furkatovna EFFECT OF VITAMIN D DICTION ON BONE MINERAL DENSITY IN MENOPAUSA WOMEN
CN101040710A (en) Health-care nutritious medicinal granules which can be took orally for controlling the incretion for women and can also be used on the skin for beauty
US20060275505A1 (en) Method and composition for increasing the alkalinity of the body
WO2020135476A1 (en) Traditional chinese medicine composition, and preparation method therefor and application thereof
Furkatovna Vitamin D Deficiency in Menopausa Women
CN112237283A (en) Donkey-hide gelatin cake and preparation method thereof
CN104606347A (en) Traditional Chinese medicine preparation for treating postmenopausal osteoporosis with hepatic and renal yin deficiency
CN106937988A (en) A kind of nti-freckle menstruation regulating Chinese medicine composition and preparation method thereof
JPH10120579A (en) Skin preparation for improving sputum for external use
US7262170B2 (en) Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof
WO2004096265A1 (en) Nutrient liquid containing human growth hormone and the preparation method thereof
CN106860509A (en) The production technology of carpet bugle capsule
JPH10114665A (en) Improver for aqueous body fluid and composition for oral administration comprising the same
CN113117028A (en) Traditional Chinese medicine composition for expelling toxin, beautifying and whitening skin and preparation method thereof
CN105287496B (en) A kind of pharmaceutical composition and preparation method thereof for treating ichthyosis
JPH10120561A (en) Skin preparation for improving sputum for external use
RU2222316C2 (en) Curative-cosmetic agent
WO2005020746A2 (en) Beautification method
RU2277929C2 (en) Method for making human organism healthy
Handa Ayurveda for Health & Beauty
CN113679800A (en) Mulberry leaf and polygonatum sibiricum kidney tonifying paste and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP